ID

14105

Description

Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT01507311

Link

https://clinicaltrials.gov/show/NCT01507311

Keywords

  1. 3/29/16 3/29/16 -
Uploaded on

March 29, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :


    No comments

    In order to download data models you must be logged in. Please log in or register for free.

    Eligibility Diabetes NCT01507311

    Eligibility Diabetes NCT01507311

    1. StudyEvent: Eligibility
      1. Eligibility Diabetes NCT01507311
    Inclusion Criteria
    Description

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693
    diagnosed with type 2 diabetes, either newly diagnosed with at least two months of diet treatment, or in current oha (oral hypoglycaemic agent) treatment with stable dose for at least six months
    Description

    Type 2 diabetes and treatment

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0011860
    UMLS CUI [2]
    C0011878
    UMLS CUI [3]
    C0359086
    bmi (body mass index) between 24 and 35 kg/m^2 (both inclusive)
    Description

    BMI

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C1305855
    fasting plasma glucose between 6 and 15 mmol/l (both inclusive)
    Description

    Fasting plasma glucose

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0583513
    anti-gad (glutamic acid decarboxylase) negative
    Description

    Anti-gad

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C1167898
    Exclusion Criteria
    Description

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    known or suspected allergy to trial product or related products
    Description

    Allergy to trial product

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0020517
    UMLS CUI [1,2]
    C3854006
    receipt of any investigational drug within three months prior to this trial
    Description

    Experimental drugs

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0304229
    recurrent severe hypoglycaemia as judged by the investigator
    Description

    Recurrent severe hypoglycaemia

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0342316
    cardiac disease or any clinically significant abnormal ecg (electrocardiogram)
    Description

    Cardiac disease or ECG

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0018799
    UMLS CUI [2]
    C0013798
    use of any drug (except oral hypoglycaemic agents (ohas)) which in the investigator's opinion could interfere
    Description

    Pharmacotherapy and drug interactions

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0013216
    UMLS CUI [1,2]
    C0687133
    with the blood glucose level (i.e., insulin, systemic corticosteroids, thiazides)
    Description

    Medication interferring with blood glucose level

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0392201
    UMLS CUI [1,2]
    C0013216
    UMLS CUI [1,3]
    C0687133
    liver or renal disease
    Description

    Liver or renal disease

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0023895
    UMLS CUI [2]
    C0022658

    Similar models

    Eligibility Diabetes NCT01507311

    1. StudyEvent: Eligibility
      1. Eligibility Diabetes NCT01507311
    Name
    Type
    Description | Question | Decode (Coded Value)
    Data type
    Alias
    Item Group
    C1512693 (UMLS CUI)
    Type 2 diabetes and treatment
    Item
    diagnosed with type 2 diabetes, either newly diagnosed with at least two months of diet treatment, or in current oha (oral hypoglycaemic agent) treatment with stable dose for at least six months
    boolean
    C0011860 (UMLS CUI [1])
    C0011878 (UMLS CUI [2])
    C0359086 (UMLS CUI [3])
    BMI
    Item
    bmi (body mass index) between 24 and 35 kg/m^2 (both inclusive)
    boolean
    C1305855 (UMLS CUI [1])
    Fasting plasma glucose
    Item
    fasting plasma glucose between 6 and 15 mmol/l (both inclusive)
    boolean
    C0583513 (UMLS CUI [1])
    Anti-gad
    Item
    anti-gad (glutamic acid decarboxylase) negative
    boolean
    C1167898 (UMLS CUI [1])
    Item Group
    C0680251 (UMLS CUI)
    Allergy to trial product
    Item
    known or suspected allergy to trial product or related products
    boolean
    C0020517 (UMLS CUI [1,1])
    C3854006 (UMLS CUI [1,2])
    Experimental drugs
    Item
    receipt of any investigational drug within three months prior to this trial
    boolean
    C0304229 (UMLS CUI [1])
    Recurrent severe hypoglycaemia
    Item
    recurrent severe hypoglycaemia as judged by the investigator
    boolean
    C0342316 (UMLS CUI [1])
    Cardiac disease or ECG
    Item
    cardiac disease or any clinically significant abnormal ecg (electrocardiogram)
    boolean
    C0018799 (UMLS CUI [1])
    C0013798 (UMLS CUI [2])
    Pharmacotherapy and drug interactions
    Item
    use of any drug (except oral hypoglycaemic agents (ohas)) which in the investigator's opinion could interfere
    boolean
    C0013216 (UMLS CUI [1,1])
    C0687133 (UMLS CUI [1,2])
    Medication interferring with blood glucose level
    Item
    with the blood glucose level (i.e., insulin, systemic corticosteroids, thiazides)
    boolean
    C0392201 (UMLS CUI [1,1])
    C0013216 (UMLS CUI [1,2])
    C0687133 (UMLS CUI [1,3])
    Liver or renal disease
    Item
    liver or renal disease
    boolean
    C0023895 (UMLS CUI [1])
    C0022658 (UMLS CUI [2])

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial